News | News By Subject | News by Disease News By Date | Search News

Lung cancer News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Genentech (RHHBY)'s $94,000-a-Year Drug Tarceva: Why Faster FDA Approvals Could Backfire     2/8/2017
The 7 Worst Clinical Disasters of 2016     12/27/2016
Concordia (CXR.TO) Kills Phase III Trial, Terminates Contract Sales, and Leaves Nasdaq Biotech Index     12/19/2016
Bristol-Myers Squibb (BMY) Looks Over Its Shoulder as Opdivo Disappoints While Merck & Co. (MRK)'s Keytruda Shines in Lung Cancer Study     10/10/2016
Genentech (RHHBY)’s Lung Cancer Drug Alecensa Gets 2nd FDA Breakthrough Status     10/5/2016
This Biotech Has the Upper Hand Over Allergan (AGN) and Gilead (GILD) in the Heated Nash Battle     9/23/2016
FDA Grants Priority Review and Breakthrough Tag for Merck & Co. (MRK)’s Keytruda     9/7/2016
Genentech (RHHBY)'s Tecentriq Shows Positive Data in Phase III Trial, Has an Upcoming Action Date in October     9/2/2016
Merck & Co. (MRK)'s Keytruda May Have an Edge Over Bristol-Myers Squibb (BMY)'s Opdivo for Cancer Doctors     8/26/2016
AstraZeneca PLC (AZN)'s Lung Cancer Drug Flunks Late-Stage Test     8/10/2016
Bristol-Myers Squibb (BMY)'s $4 Billion Disaster Sends Partner Ono Pharma (OPHLY)'s Stock Plunging     8/9/2016
Bristol-Myers Squibb (BMY)'s Failed Lung Cancer Data Sends Stock Plunging     8/5/2016
Boehringer Ingelheim Halts Two Phase III Trials for Lung Cancer Drug Gilotrif     7/27/2016
AbbVie (ABBV) Partners Up With Bristol-Myers Squibb (BMY) in Combo Treatment for Lung Cancer     7/25/2016
AstraZeneca PLC (AZN)'s TAGRISSO Met Primary Endpoint in Late-Stage Lung Cancer Trial     7/18/2016

News from Around the Web
Sought-After Tesaro (TSRO) Sees A $5 Billion Opportunity For Its Cancer Drug     2/17/2017
Liquid Biopsy For Lung Cancer Provides Rapid Results At Low Cost And No Trauma, Stanford University Study     1/6/2017
Czech Scientists Develop Human Lung Model To Aid Treatments, Brno University Of Technology Study     11/29/2016
Balance Of Power Shifts With Merck & Co. (MRK)'s Keytruda First-Line Therapy Approval In Lung Cancer     10/26/2016
Genentech (RHHBY)’s Tecentriq Wins Second Approval of the Year, This Time for Lung Cancer     10/19/2016
AI Beats Doctors At Visual Diagnosis, Observes Many Times More Lung Cancer Signals, Stanford University Study     8/19/2016
Transgenomic, Inc. (TBIO) Launches First Commercially Available CLIA Test For Detection Of EGFR C797S Mutations That Predict Resistance To 3rd Generation Kinase Therapies For Lung Cancer     7/25/2016
University of Louisville Teams Up With Company To Help Lung Cancer Diagnosis     6/15/2016
This Diet Ups Your Lung Cancer Even If You Don't Smoke, MD Anderson Cancer Center Study     3/9/2016
Biotech Startup Yihuo Bio To Produce New Device For Early Detection Of Lung Cancer     2/29/2016
Could A Lung Cancer Drug Work Better With Coke? Erasmus MC Study     2/16/2016
This Lung Cancer Drug May Not Be What It Seems, Chemists Say     1/4/2016
Study Suggests Indi's Xpresys Test Could Reduce Invasive Procedures In NSCLC Diagnosis     12/23/2015
A New Way To Test For Rejection or Infection Following Lung Transplantation, Stanford University Study     10/15/2015
Beware: Asbestos Found In Some Crayons, Toys From China     7/8/2015

Press Releases
Novartis AG (NVS)'s Cancer Drug Gets a Fast Track Ticket From the FDA     2/23/2017
First Patient Enrolled In NovoCure’s Phase III Pivotal LUNAR Trial Testing Tumor Treating Fields For The Treatment Of Advanced Non-Small Cell Lung Cancer After Failing Platinum-Based Therapy     2/15/2017
Agena Biosciences Release: Multiplexed Analysis Of ALK, ROS1, And RET Rearrangements In Lung Cancer Enabled By The Massarray System     2/9/2017
Japanese Regulators Approve AmoyDx’s ROS1 Fusion CDx For Lung Cancer Drug     2/3/2017
Addario Lung Cancer Medical Institute And Scancell (SCNLF) Form Partnership To Advance Lung Cancer Vaccine Clinical Trials     1/30/2017
OSE Immunotherapeutics Release: Company Announces That The Independent Data Monitoring Committee (IDMC) Recommends Continuation Of Pivotal Phase 3 Clinical Trial Of Tedopi In Non-Small Cell Lung Cancer     1/24/2017
AstraZeneca PLC (AZN) Release: Biopharma Rejigs Primary Endpoints for Mystic Lung Cancer Trial     1/17/2017
Hutchison China MediTech (Chi-Med) Release: Biopharma Initiates A Phase II Combination Study Of Fruquintinib With Iressa (Gefitinib) In First-Line Non-Small Cell Lung Cancer     1/16/2017
Incyte (INCY) And Merck & Co. (MRK) To Advance Clinical Development Program Investigating The Combination Of Epacadostat With KEYTRUDA (Pembrolizumab)     1/9/2017
Cota Publishes New Study Showing Some Lung Cancer Patients Are Being Left Behind In Genomic Revolution     1/9/2017
Genprex Announces Positive Interim Data From Phase II Clinical Trial Of Oncoprex For Late Stage Non-Small Cell Lung Cancer     1/6/2017
Inventiva Announces Initiation Of Phase IIb Clinical Trial Of IVA337 For Treatment Of Non-Alcoholic Steatohepatitis (NASH)     1/3/2017
Bavarian Nordic (BAVA.CO) Initiates Trial Of CV301 In Combination With Nivolumab In Patients With Lung Cancer     12/29/2016
Yuhan Terminates Licensing Deal with Chinese Partner for its Lung Cancer Drug     12/28/2016
Merck & Co. (MRK) Release: KEYTRUDA (Pembrolizumab) Approved As First Anti-PD-1 Therapy In Japan For First-Line Treatment Of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express High Levels Of PD-L1     12/19/2016

//-->